Matthew A. Naylor

1.5k citations

53 papers · 1.1k indexed · h-index 19

Co-authors: Ian J. Stratford Michael R.L. Stratford Steven A. Everett Peter Wardman John Nolan G.E. Adams Peter D. Davis Sally A. Hill
Topics: Synthesis and Biological Evaluation (11 papers)Bioactive Compounds and Antitumor Agents (9 papers)Synthesis and Characterization of Heterocyclic Compounds (8 papers)
Cited by: Toxicology Cancer Research Organic Chemistry
Journals: Journal of the American Chemical Society Journal of Medicinal Chemistry British Journal of Cancer
Partner nations: United Kingdom South Africa United States

In The Last Decade

Matthew A. Naylor

53 papers receiving 1.0k citations

Peers

Countries citing papers authored by Matthew A. Naylor

Since Specialization

Citations

This map shows the geographic impact of Matthew A. Naylor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew A. Naylor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew A. Naylor more than expected).

Fields of papers citing papers by Matthew A. Naylor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew A. Naylor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew A. Naylor. The network helps show where Matthew A. Naylor may publish in the future.

Co-authorship network of co-authors of Matthew A. Naylor

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew A. Naylor. A scholar is included among the top collaborators of Matthew A. Naylor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew A. Naylor. Matthew A. Naylor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Gonad development in farmed male and female South African abalone, Haliotis midae, fed artificial and natural diets under a range of husbandry conditions 2022 ·Aquaculture International ·(unknown),Simon Menanteau‐Ledouble,Matthew A. Naylor,Horst Kaiser,Mansour El‐Matbouli	3
2	The effects of competitor density on aggressive behaviour and resource defence in a Poeciliid fish 2013 ·Journal of Applied Ichthyology ·Horst Kaiser,(unknown),(unknown),Matthew A. Naylor,Rob H. Field,(unknown),Kit Magellan	3
3	Hypoxia-driven elimination of thiopurines from their nitrobenzyl prodrugs 2007 ·Bioorganic & Medicinal Chemistry Letters ·Peter Thomson,Matthew A. Naylor,Michael R.L. Stratford,(unknown),Sally A. Hill,Kantilal B. Patel,Peter Wardman,Peter D. Davis	15
4	ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. 2002 ·Oxford University Research Archive (ORA) (University of Oxford) ·Peter D. Davis,Graeme J. Dougherty,David C. Blakey,Susan Galbraith,Gillian M. Tozer,Angela Holder,Matthew A. Naylor,John Nolan,Michael R.L. Stratford,David J. Chaplin,Sally A. Hill	200
5	Enhancement of vascular targeting by inhibitors of nitric oxide synthase 2002 ·International Journal of Radiation OncologyBiologyPhysics ·Peter D. Davis,Gillian M. Tozer,Matthew A. Naylor,Peter Thomson,Gemma Lewis,Sally A. Hill	12
6	Recent Advances in Bioreductive Drug Targeting 2001 ·Mini-Reviews in Medicinal Chemistry ·Matthew A. Naylor,(unknown)	29
7	1-Methylindole-3-carboxaldehyde oxime derivatives 2001 ·Acta Crystallographica Section C Crystal Structure Communications ·Robert W. Janes,B.S. Potter,Matthew A. Naylor,(unknown),Kantilal B. Patel,Michael R.L. Stratford,Peter Wardman,Steven A. Everett	1
8	The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions 2000 ·Biochemical Pharmacology ·Mark Saunders,Mohammed Jaffar,Adam V. Patterson,John Nolan,Matthew A. Naylor,Roger M. Phillips,Adrian L. Harris,Ian J. Stratford	33
9	Prodrugs for targeting hypoxic tissues: Regiospecific elimination of aspirin from reduced indolequinones 1999 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Steven A. Everett,Matthew A. Naylor,Stephen Moore,(unknown),K B Patel,M.R.L. Stratford,John Nolan,Peter Wardman,Ian J. Stratford	20
10	Heterocyclic analogues of l -citrulline as inhibitors of the isoforms of nitric oxide synthase (NOS) and identification of N δ -(4,5-dihydrothiazol-2-yl)ornithine as a potent inhibitor 1999 ·Bioorganic & Medicinal Chemistry ·(unknown),Edwin C. Chinje,Matthew A. Naylor,Mohammed Jaffar,Ian J. Stratford,Michael D. Threadgill	18
11	Bioreductively-activated prodrugs for targeting hypoxic tissues: Elimination of aspirin from 2-nitroimidazole derivatives 1999 ·Bioorganic & Medicinal Chemistry Letters ·Steven A. Everett,Matthew A. Naylor,K B Patel,M.R.L. Stratford,Peter Wardman	28
12	Structural Requirements for EO9 Toxicity and Dependence on P450 Reductase for Activation 1996 ·British Journal of Cancer ·(unknown),(unknown),(unknown),Matthew A. Naylor,(unknown),(unknown),Ian J. Stratford	2
13	Fused pyrazine mono-N-oxides as bioreductive drugs III. Characterization of RB 90740 in vitro and in vivo 1995 ·Anti-Cancer Drugs ·Matthew A. Naylor,G.E. Adams,(unknown),Soren Cole,(unknown),Naomi Robertson,Dietmar W. Siemann,Miriam A. Stephens,Ian J. Stratford	11
14	Pharmacokinetics, metabolism and distribution of 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-al pyrido [3,2-el pyrazine-5-oxide in C3H mice 1994 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown),(unknown),Matthew A. Naylor,E.M. Fielden,Soren Cole,G.E. Adams,Ian J. Stratford	4
15	Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT) 1994 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown),(unknown),G.E. Adams,Matthew A. Naylor,J. M. Sansom,Ian J. Stratford	6
16	Radiolytic and photochemical reduction of the hypoxic cytotoxin 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-a] pyrido [3,2-e] pyrazine 5-oxide (RB90740) and a potential mechanism for hypoxia-selective toxicity 1994 ·International Journal of Radiation OncologyBiologyPhysics ·Matthew A. Naylor,(unknown),John Nolan,Peter O’Neill,E.M. Fielden,G.E. Adams,Ian J. Stratford	6
17	2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivatives 1992 ·Journal of Medicinal Chemistry ·Matthew A. Naylor,Michael D. Threadgill,Paul B. Webb,Ian J. Stratford,Miriam A. Stephens,E.M. Fielden,G.E. Adams	14
18	Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins 1991 ·Journal of Medicinal Chemistry ·Michael D. Threadgill,Paul B. Webb,P. O’Neill,Matthew A. Naylor,Miriam A. Stephens,Ian J. Stratford,Soren Cole,G.E. Adams,E.M. Fielden	20
19	Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins 1990 ·Journal of Medicinal Chemistry ·Matthew A. Naylor,Miriam A. Stephens,Soren Cole,Michael D. Threadgill,Ian J. Stratford,P. O’Neill,E.M. Fielden,G.E. Adams	19
20	Extensions of the Willgerodt Reaction. I 1953 ·Journal of the American Chemical Society ·Matthew A. Naylor,(unknown)	5

About Matthew A. Naylor

Matthew A. Naylor is a scholar working on Toxicology, Organic Chemistry and Biophysics, having authored 53 papers that have together received 1.1k indexed citations. Recurring topics across this work include Synthesis and Biological Evaluation (11 papers), Bioactive Compounds and Antitumor Agents (9 papers) and Synthesis and Characterization of Heterocyclic Compounds (8 papers). The work is most often cited by research in Toxicology (168 citations), Cancer Research (258 citations) and Organic Chemistry (474 citations). Matthew A. Naylor has collaborated with scholars based in United Kingdom, South Africa and United States. Frequent co-authors include Ian J. Stratford, Michael R.L. Stratford, Steven A. Everett, Peter Wardman, John Nolan, G.E. Adams, Peter D. Davis, Sally A. Hill, Mohammed Jaffar and E.M. Fielden. Their work appears in journals such as Journal of the American Chemical Society, Journal of Medicinal Chemistry and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact